Literature DB >> 27554778

Effect of Hypoglycemia on the Incidence of Revision in Total Knee Arthroplasty.

Martin W Roche1, Tsun Yee Law1, Jacob J Triplet2, Zachary S Hubbard3, Jennifer Kurowicki1, Sam Rosas1.   

Abstract

BACKGROUND: It is well established that diabetic patients undergoing total knee arthroplasty (TKA) are more susceptible to infection, problematic wound healing, and overall higher complication rates. However, a paucity in current literature exists. The purpose of this study was to determine the effect of hypoglycemia on TKA revision (rTKA) incidence by analyzing a national private payer database for procedures performed between 2007 and 2015 Q1 Q2.
METHODS: A retrospective review of a national private payer database within the PearlDiver Supercomputer application for patients undergoing TKA with blood glucose levels from 20 to 219 mg/mL, in 10-mg/mL increments, was conducted. Patients who underwent TKA were identified by Current Procedural Terminology (CPT) and International Classification of Disease (ICD) codes. Glucose ranges were identified by filtering for Logical Observation Identifiers Names and Codes within the PearlDiver database. Patients with diagnosed diabetes mellitus type I or II were excluded by using ICD-9 codes 250.00-250.03, 250.10-250.13, and 250.20-250.21. rTKA causes including mechanical loosening, failure/break, periprosthetic fracture, osteolysis, infection, pain, arthrofibrosis, instability, and trauma were identified with CPT and ICD-9 codes. Statistical analysis was primarily descriptive.
RESULTS: Our query returned 264,824 TKAs, of which 12,852 (4.9%) were revised. Most TKAs were performed with a glucose of 70-99 mg/mL (26.1%), followed by 100-109 mg/mL (18.5%). Patients with TKAs performed with glucose 20-29 mg/mL had the highest rate of revision (17.2%; P < .001). Infection was the most common cause of revision among all glucose ranges (P < .001).
CONCLUSION: Infection remains one of the most common causes of rTKA irrespective of glucose level. Our results suggest that hypoglycemia may increase revision rates among TKA patients. Tight glycemic control before and during surgery may be warranted.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypoglycemia; knee replacement; revision; revision arthroplasty; total knee arthroplasty

Mesh:

Substances:

Year:  2016        PMID: 27554778     DOI: 10.1016/j.arth.2016.07.014

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  5 in total

1.  Perioperative glycemic status is linked to postoperative complications in non-intensive care unit patients with type-2 diabetes: a retrospective study.

Authors:  Takeshi Oba; Mototsugu Nagao; Shunsuke Kobayashi; Yuji Yamaguchi; Tomoko Nagamine; Kyoko Tanimura-Inagaki; Izumi Fukuda; Hitoshi Sugihara
Journal:  Ther Adv Endocrinol Metab       Date:  2022-05-19       Impact factor: 4.435

2.  Previous History of Breast Cancer Increases Rates of Pulmonary Embolism and Costs after Total Knee Arthroplasty: An Evaluation of 185,114 Matched Patients.

Authors:  Samuel Rosas; T David Luo; Alexander H Jinnah; Alejandro Marquez-Lara; Martin W Roche; Cynthia L Emory
Journal:  J Knee Surg       Date:  2018-04-04       Impact factor: 2.757

3.  Hot spots and trends in knee revision research since the 21st century: a bibliometric analysis.

Authors:  Kelei Zhai; Weifeng Ma; Tao Huang
Journal:  Ann Transl Med       Date:  2021-03

4.  Season of the year influences infection rates following total hip arthroplasty.

Authors:  Samuel Rosas; Alvin C Ong; Leonard T Buller; Karim G Sabeh; Tsun Yee Law; Martin W Roche; Victor H Hernandez
Journal:  World J Orthop       Date:  2017-12-18

5.  Development of an Integrated Platform Using Multidisciplinary Real-World Data to Facilitate Biomarker Discovery for Medical Products.

Authors:  Stefan Dabic; Yasameen Azarbaijani; Tigran Karapetyan; Nilsa Loyo-Berrios; Vahan Simonyan; Terrie Kitchner; Murray Brilliant; Yelizaveta Torosyan
Journal:  Clin Transl Sci       Date:  2019-09-12       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.